ALNY•businesswire•
Alnylam Launches “Alnylam 2030” Strategy to Drive Next Era of Growth and Patient Impact
Summary
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced its new five-year strategy, “Alnylam 2030,” focused on scaling the Company’s operations through achieving leadership in ATTR amyloidosis, driving long-term growth through sustainable innovation, and delivering exceptional financial results with discipline and agility. Alnylam also today reported preliminary* fourth quarter and full year 2025 global net product
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on January 11, 2026 by businesswire